GALT Stock Overview
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Galectin Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.38 |
| 52 Week High | US$4.27 |
| 52 Week Low | US$1.28 |
| Beta | 0.88 |
| 1 Month Change | 38.52% |
| 3 Month Change | 96.51% |
| 1 Year Change | 93.14% |
| 3 Year Change | -18.75% |
| 5 Year Change | -21.03% |
| Change since IPO | -71.83% |
Recent News & Updates
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25
Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09Shareholder Returns
| GALT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -2.5% | -3.2% |
| 1Y | 93.1% | -3.7% | 19.3% |
Return vs Industry: GALT exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: GALT exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| GALT volatility | |
|---|---|
| GALT Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GALT's share price has been volatile over the past 3 months.
Volatility Over Time: GALT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 28 | Joel Lewis | galectintherapeutics.com |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration.
Galectin Therapeutics Inc. Fundamentals Summary
| GALT fundamental statistics | |
|---|---|
| Market cap | US$189.43m |
| Earnings (TTM) | -US$44.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs GALT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$44.81m |
| Earnings | -US$44.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -119.1% |
How did GALT perform over the long term?
See historical performance and comparison